Use of the mouse ear vesicant model to evaluate the effectiveness of ebselen as a countermeasure to the nitrogen mustard mechlorethamine

Anju Lulla, Sandra Reznik, Louis Trombetta, Blase Billack

Research output: Contribution to journalArticle

Abstract

Previous studies in this and other laboratories have demonstrated that ebselen (EB-1), an organoselenium compound, spares cells from mechlorethamine (HN2) toxicity in vitro. In the present study, the hypothesis that EB-1 will reduce dermal toxicity of HN2 in vivo is put forward and found to have merit. Using the mouse ear vesicant model (MEVM), HN2, applied topically, showed a dose-dependent effect upon ear swelling and thickness 24h after treatment; whereas tissue injury consistent with vesication was observed at the higher test doses of HN2 (≥ 0.250μmol per ear). To examine HN2 countermeasure activity using the MEVM, either hydrocortisone (HC), as a positive control, or EB-1, the test countermeasure, was administered as three topical treatments 15min, 4 and 8h after HN2 exposure. Using this approach, both HC and EB-1 were found to reduce tissue swelling associated with HN2 toxicity 24h after exposure to the vesicant. Taken together, these data demonstrate for the first time the effectiveness of EB-1 as a vesicant countermeasure in a relevant in vivo model.

Original languageEnglish (US)
Pages (from-to)1373-1378
Number of pages6
JournalJournal of Applied Toxicology
Volume34
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Organoselenium Compounds
Protective Agents
Mechlorethamine
Azoles
Irritants
Skin
Animals
Toxicity
Swelling
Hydrocortisone
Tissue
ebselen

Keywords

  • Countermeasure
  • Ebselen
  • Mechlorethamine
  • Mouse ear
  • Nitrogen mustard
  • Organoselenium

ASJC Scopus subject areas

  • Toxicology

Cite this

Use of the mouse ear vesicant model to evaluate the effectiveness of ebselen as a countermeasure to the nitrogen mustard mechlorethamine. / Lulla, Anju; Reznik, Sandra; Trombetta, Louis; Billack, Blase.

In: Journal of Applied Toxicology, Vol. 34, No. 12, 01.12.2014, p. 1373-1378.

Research output: Contribution to journalArticle

@article{4e5607cadebb45779c67304339216362,
title = "Use of the mouse ear vesicant model to evaluate the effectiveness of ebselen as a countermeasure to the nitrogen mustard mechlorethamine",
abstract = "Previous studies in this and other laboratories have demonstrated that ebselen (EB-1), an organoselenium compound, spares cells from mechlorethamine (HN2) toxicity in vitro. In the present study, the hypothesis that EB-1 will reduce dermal toxicity of HN2 in vivo is put forward and found to have merit. Using the mouse ear vesicant model (MEVM), HN2, applied topically, showed a dose-dependent effect upon ear swelling and thickness 24h after treatment; whereas tissue injury consistent with vesication was observed at the higher test doses of HN2 (≥ 0.250μmol per ear). To examine HN2 countermeasure activity using the MEVM, either hydrocortisone (HC), as a positive control, or EB-1, the test countermeasure, was administered as three topical treatments 15min, 4 and 8h after HN2 exposure. Using this approach, both HC and EB-1 were found to reduce tissue swelling associated with HN2 toxicity 24h after exposure to the vesicant. Taken together, these data demonstrate for the first time the effectiveness of EB-1 as a vesicant countermeasure in a relevant in vivo model.",
keywords = "Countermeasure, Ebselen, Mechlorethamine, Mouse ear, Nitrogen mustard, Organoselenium",
author = "Anju Lulla and Sandra Reznik and Louis Trombetta and Blase Billack",
year = "2014",
month = "12",
day = "1",
doi = "10.1002/jat.2969",
language = "English (US)",
volume = "34",
pages = "1373--1378",
journal = "Journal of Applied Toxicology",
issn = "0260-437X",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Use of the mouse ear vesicant model to evaluate the effectiveness of ebselen as a countermeasure to the nitrogen mustard mechlorethamine

AU - Lulla, Anju

AU - Reznik, Sandra

AU - Trombetta, Louis

AU - Billack, Blase

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Previous studies in this and other laboratories have demonstrated that ebselen (EB-1), an organoselenium compound, spares cells from mechlorethamine (HN2) toxicity in vitro. In the present study, the hypothesis that EB-1 will reduce dermal toxicity of HN2 in vivo is put forward and found to have merit. Using the mouse ear vesicant model (MEVM), HN2, applied topically, showed a dose-dependent effect upon ear swelling and thickness 24h after treatment; whereas tissue injury consistent with vesication was observed at the higher test doses of HN2 (≥ 0.250μmol per ear). To examine HN2 countermeasure activity using the MEVM, either hydrocortisone (HC), as a positive control, or EB-1, the test countermeasure, was administered as three topical treatments 15min, 4 and 8h after HN2 exposure. Using this approach, both HC and EB-1 were found to reduce tissue swelling associated with HN2 toxicity 24h after exposure to the vesicant. Taken together, these data demonstrate for the first time the effectiveness of EB-1 as a vesicant countermeasure in a relevant in vivo model.

AB - Previous studies in this and other laboratories have demonstrated that ebselen (EB-1), an organoselenium compound, spares cells from mechlorethamine (HN2) toxicity in vitro. In the present study, the hypothesis that EB-1 will reduce dermal toxicity of HN2 in vivo is put forward and found to have merit. Using the mouse ear vesicant model (MEVM), HN2, applied topically, showed a dose-dependent effect upon ear swelling and thickness 24h after treatment; whereas tissue injury consistent with vesication was observed at the higher test doses of HN2 (≥ 0.250μmol per ear). To examine HN2 countermeasure activity using the MEVM, either hydrocortisone (HC), as a positive control, or EB-1, the test countermeasure, was administered as three topical treatments 15min, 4 and 8h after HN2 exposure. Using this approach, both HC and EB-1 were found to reduce tissue swelling associated with HN2 toxicity 24h after exposure to the vesicant. Taken together, these data demonstrate for the first time the effectiveness of EB-1 as a vesicant countermeasure in a relevant in vivo model.

KW - Countermeasure

KW - Ebselen

KW - Mechlorethamine

KW - Mouse ear

KW - Nitrogen mustard

KW - Organoselenium

UR - http://www.scopus.com/inward/record.url?scp=84911806124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911806124&partnerID=8YFLogxK

U2 - 10.1002/jat.2969

DO - 10.1002/jat.2969

M3 - Article

C2 - 24347431

AN - SCOPUS:84911806124

VL - 34

SP - 1373

EP - 1378

JO - Journal of Applied Toxicology

JF - Journal of Applied Toxicology

SN - 0260-437X

IS - 12

ER -